[
  {
    "ts": null,
    "headline": "The past three years for Pfizer (NYSE:PFE) investors has not been profitable",
    "summary": "For many investors, the main point of stock picking is to generate higher returns than the overall market. But the risk...",
    "url": "https://finnhub.io/api/news?id=7d9be27b8f9d87dfe07b1ad793f78dcaccc0b54eaf36b0f5371d85a8f9ab7433",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750341617,
      "headline": "The past three years for Pfizer (NYSE:PFE) investors has not been profitable",
      "id": 135396959,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "For many investors, the main point of stock picking is to generate higher returns than the overall market. But the risk...",
      "url": "https://finnhub.io/api/news?id=7d9be27b8f9d87dfe07b1ad793f78dcaccc0b54eaf36b0f5371d85a8f9ab7433"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?",
    "summary": "PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance.",
    "url": "https://finnhub.io/api/news?id=2885992d608d46e02781df583c8263646f5419f5610aeaf38b0f0270bf210e57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750340820,
      "headline": "Pfizer Boasts Strong Oncology Portfolio: Can it Sustain Growth?",
      "id": 135396878,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance.",
      "url": "https://finnhub.io/api/news?id=2885992d608d46e02781df583c8263646f5419f5610aeaf38b0f0270bf210e57"
    }
  },
  {
    "ts": null,
    "headline": "Gene Therapy Has Lost Support on Wall Street. There’s Still Hope for Big Cures.",
    "summary": "Five years ago, scientists and investors were excited about gene therapy offering one-and-done cures for deadly diseases. Today, much of the enthusiasm has dried up.",
    "url": "https://finnhub.io/api/news?id=fc49b2b4a25a5650ecda16800c0f29ff3170d3d09f746cc45139d65470ca0e2e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750316400,
      "headline": "Gene Therapy Has Lost Support on Wall Street. There’s Still Hope for Big Cures.",
      "id": 135389325,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Five years ago, scientists and investors were excited about gene therapy offering one-and-done cures for deadly diseases. Today, much of the enthusiasm has dried up.",
      "url": "https://finnhub.io/api/news?id=fc49b2b4a25a5650ecda16800c0f29ff3170d3d09f746cc45139d65470ca0e2e"
    }
  }
]